106 related articles for article (PubMed ID: 16320268)
41. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
[TBL] [Abstract][Full Text] [Related]
42. Baseline and treatment effect heterogeneity for survival times between centers using a random effects accelerated failure time model with flexible error distribution.
Komárek A; Lesaffre E; Legrand C
Stat Med; 2007 Dec; 26(30):5457-72. PubMed ID: 17910009
[TBL] [Abstract][Full Text] [Related]
43. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
[TBL] [Abstract][Full Text] [Related]
44. Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).
Arico M; Ziino O; Valsecchi MG; Cazzaniga G; Baronci C; Messina C; Pession A; Santoro N; Basso G; Conter V;
Cancer; 2008 Aug; 113(3):515-21. PubMed ID: 18521927
[TBL] [Abstract][Full Text] [Related]
45. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
[TBL] [Abstract][Full Text] [Related]
46. Generalized log-rank test for mixed interval-censored failure time data.
Zhao Q; Sun J
Stat Med; 2004 May; 23(10):1621-9. PubMed ID: 15122741
[TBL] [Abstract][Full Text] [Related]
47. A stochastic model for censored-survival data in the presence of an auxiliary variable.
Lagakos SW
Biometrics; 1976 Sep; 32(3):551-9. PubMed ID: 963170
[TBL] [Abstract][Full Text] [Related]
48. Semi-parametric modelling of the distribution of the baseline risk in meta-analysis.
Ghidey W; Lesaffre E; Stijnen T
Stat Med; 2007 Dec; 26(30):5434-44. PubMed ID: 17893888
[TBL] [Abstract][Full Text] [Related]
49. Prospective accuracy for longitudinal markers.
Zheng Y; Heagerty PJ
Biometrics; 2007 Jun; 63(2):332-41. PubMed ID: 17688486
[TBL] [Abstract][Full Text] [Related]
50. Significance of four MRD markers in MRD-based treatment strategy for childhood acute lymphoblastic leukemia.
Sawada A; Sakata N; Kishimoto T; Higuchi B; Koyama M; Kondo O; Sato E; Okamura T; Yasui M; Inoue M; Yoshioka A; Kawa K
Leuk Res; 2009 Dec; 33(12):1710-3. PubMed ID: 19596431
[TBL] [Abstract][Full Text] [Related]
51. A time-dependent discrimination index for survival data.
Antolini L; Boracchi P; Biganzoli E
Stat Med; 2005 Dec; 24(24):3927-44. PubMed ID: 16320281
[TBL] [Abstract][Full Text] [Related]
52. A semi-Markov model for multistate and interval-censored data with multiple terminal events. Application in renal transplantation.
Foucher Y; Giral M; Soulillou JP; Daures JP
Stat Med; 2007 Dec; 26(30):5381-93. PubMed ID: 17987670
[TBL] [Abstract][Full Text] [Related]
53. Regression analysis of incomplete medical cost data.
Lin DY
Stat Med; 2003 Apr; 22(7):1181-200. PubMed ID: 12652561
[TBL] [Abstract][Full Text] [Related]
54. Residual analysis in linear regression models with an interval-censored covariate.
Topp R; Gómez G
Stat Med; 2004 Nov; 23(21):3377-91. PubMed ID: 15490424
[TBL] [Abstract][Full Text] [Related]
55. Multistate analysis of interval-censored longitudinal data: application to a cohort study on performance status among patients diagnosed with cancer.
Sutradhar R; Barbera L; Seow H; Howell D; Husain A; Dudgeon D
Am J Epidemiol; 2011 Feb; 173(4):468-75. PubMed ID: 21193535
[TBL] [Abstract][Full Text] [Related]
56. Stochastic EM algorithm for doubly interval-censored data.
Dejardin D; Lesaffre E
Biostatistics; 2013 Sep; 14(4):766-78. PubMed ID: 23728851
[TBL] [Abstract][Full Text] [Related]
57. Performance of binary markers for censored failure time outcome: nonparametric approach based on proportions.
Antolini L; Valsecchi MG
Stat Med; 2012 May; 31(11-12):1113-28. PubMed ID: 22161769
[TBL] [Abstract][Full Text] [Related]
58. A more appropriate statistical method for analyzing mortality data in shock research.
Knapp RG; Wise WC
Circ Shock; 1985; 16(4):375-81. PubMed ID: 3836029
[TBL] [Abstract][Full Text] [Related]
59. A penalized likelihood approach for an illness-death model with interval-censored data: application to age-specific incidence of dementia.
Joly P; Commenges D; Helmer C; Letenneur L
Biostatistics; 2002 Sep; 3(3):433-43. PubMed ID: 12933608
[TBL] [Abstract][Full Text] [Related]
60. A test for the relationship between a time-varying marker and both recovery and progression with missing data.
Schoenfeld DA; Rajicic N; Ficociello LH; Finkelstein DM
Stat Med; 2011 Mar; 30(7):718-24. PubMed ID: 21394748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
